Literature DB >> 3312304

The HLA system: structure and function.

W F Bodmer1.   

Abstract

The HLA system is the major histocompatibility system of man and was found through a search for blood group-like determinants on white blood cells that would be effective in matching for transplantation. The HLA system has its counterparts in other species of mammals, birds, and reptiles including the much studied H2 system of the mouse. The HLA system started from a series of antigens defined by a combination of relatively crude serology and genetics, supported by extensive statistical analysis. It has turned out to be a complex genetic region determining two major sets of cell surface products which mediate essential functional interactions between cells of the immune system, and so have a major role in the control of the immune response. Polymorphism in the HLA region is thus associated with a wide variety of diseases with an immune aetiology.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312304      PMCID: PMC1141164          DOI: 10.1136/jcp.40.9.948

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  50 in total

Review 1.  HLA and trophoblastic tumours.

Authors:  S D Lawler
Journal:  Br Med Bull       Date:  1978-09       Impact factor: 4.291

2.  The human mixed lymphocyte-endothelium culture interaction.

Authors:  H Hirschberg; S A Evensen; T Henriksen; E Thorsby
Journal:  Transplantation       Date:  1975-06       Impact factor: 4.939

Review 3.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  Detection of B-cell-specific alloantibodies in pregnancy sera in the lymphocytotoxicity and the indirect immunofluorescence techniques.

Authors:  F Décary; L van Helden-Henningheim; D van Griethuysen; F M Helmerhorst; A J van der Werf; C P Engelfriet
Journal:  Tissue Antigens       Date:  1979-07

5.  The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin.

Authors:  B Arce-Gomez; E A Jones; C J Barnstable; E Solomon; W F Bodmer
Journal:  Tissue Antigens       Date:  1978-02

6.  Immunology and the fetus.

Authors: 
Journal:  Lancet       Date:  1978-02-11       Impact factor: 79.321

7.  Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity.

Authors:  P C Doherty; R V Blanden; R M Zinkernagel
Journal:  Transplant Rev       Date:  1976

8.  HLA structure and function: a contemporary view.

Authors:  W F Bodmer
Journal:  Tissue Antigens       Date:  1981-01

9.  Expression of Ia-like antigens on cultured human malignant melanoma cell lines.

Authors:  R J Winchester; C Y Wang; A Gibofsky; H G Kunkel; K O Lloyd; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

10.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

View more
  20 in total

1.  Constraints on haplotype structure and variable gene frequencies suggest a functional hierarchy within cattle MHC class I.

Authors:  Gemma F Codner; James Birch; John A Hammond; Shirley A Ellis
Journal:  Immunogenetics       Date:  2012-03-28       Impact factor: 2.846

2.  Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin's gastric lymphoma patients.

Authors:  Alexander Darom; Ilias P Gomatos; Emmanuel Leandros; Emmu Chatzigianni; Dimitris Panousopoulos; Manousos M Konstadoulakis; George Androulakis
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

3.  HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia?

Authors:  Amal Baccar Harrath; Besma Yacoubi Loueslati; Wafa Troudi; Slama Hmida; Syrine Sedkaoui; Amel Dridi; Afef Jridi; Farhat Ben Ayed; Khaled Ben Rhomdhane; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

4.  Genetic analysis of HLA in the U.S. Schmiedenleut Hutterites.

Authors:  D D Kostyu; C L Ober; D V Dawson; M Ghanayem; S Elias; A O Martin
Journal:  Am J Hum Genet       Date:  1989-08       Impact factor: 11.025

5.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

6.  Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Authors:  M J Browning; P Krausa; A Rowan; D C Bicknell; J G Bodmer; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

Authors:  M E Smith; S G Marsh; J G Bodmer; K Gelsthorpe; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene.

Authors:  M E Sunday; K J Isselbacher; S Gattoni-Celli; C G Willett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.

Authors:  S Apasov; M Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.